The diabetes scientific community will convene virtually at the American Diabetes Association’s 81st Scientific Sessions from June 25-29 to present the most groundbreaking discoveries and cutting-edge innovations in diabetes research, prevention, and care. Scientists from the Diabetes Research Institute will once again be involved, presenting their work and chairing multiple sessions.
DRI Director Dr. Camillo Ricordi will give an overview on the status of islet cell transplantation in the US. Acknowledged by his peers as one of the world’s leading scientists in cell transplantation, Dr. Ricordi is well-known for inventing the machine that made it possible to isolate large numbers of islet cells (insulin-producing cells) from the human pancreas and for performing the first series of successful clinical islet transplants that reversed diabetes. The procedure is now used by laboratories performing clinical islet transplants worldwide. He has also developed highly innovative strategies with the objective to transplant cells and organs without the continuous requirement for anti-rejection drugs and for the reversal of autoimmune disease conditions.
DRI Deputy Director Dr. Jay Skyler will participate in one of the event’s most popular presentations, The Year in Review—Highlights of the Past Year in Basic, Translational, and Clinical Sciences. After serving as the Year in Review session chairperson in 2019, Dr. Skyler will be presenting this year on the most recent additions to the clinician’s toolkit for treating type 1 and type 2 diabetes.
With a career that spans five decades, Dr. Skyler is one of the preeminent leaders in the clinical aspects of diabetes. He previously served as Study Chairman for the NIH Diabetes Prevention Trial for T1D (DPT-1) and its successor the T1D TrialNet, a nationwide (and global) network conducting clinical trials to interdict type 1 diabetes. Dr. Skyler currently is Chair of the Strategy Advisory Group for INNODIA, a European consortium of academic and industry groups developing innovative approaches toward understanding and arresting type 1 diabetes. He was President of the American Diabetes Association and Vice-President of the International Diabetes Federation. He was founding Editor-in-Chief of Diabetes Care, the clinical journal of the American Diabetes Association.
See the complete list of DRI participants in this year’s Scientific Sessions below and stay tuned for a recap of their presentations following the event. If you are interested in receiving more content about these presentations, please send us an email.
ADA 81st Scientific Sessions
June 25-29, 2021
Presentations and Abstracts
Camillo Ricordi, MD
Oral Presentation – June 28, 2021
Title: Status of Islet Transplantation in the U.S.
Jay Skyler, MD, MACP
Chair – June 25, 2021
Theme Area: Clinical Diabetes/Therapeutics
Title: Implementing Type 1 Diabetes Immune Intervention in Clinical Practice
Oral Presentation – June 26, 2021
Title: Novel Biomarkers for Understanding Diabetes Heterogeneity
75-OR Marked Heterogeneity in Nondiabetic, Autoantibody-Positive (Ab+) Individuals with Dysglycemia: Implications for Type 1 Diabetes (T1D) Staging
Oral Presentation – June 27, 2021
Title: The Year in Review—Clinical Science
Oral Presentation – June 28, 2021
Title: Management of Type 1 Diabetes in Adults—2021 Draft ADA/EASD Consensus Report
Emergent and Future Perspectives
Poster Presentation – June 28, 2021
Title: 1117-P Characterizing Glucose/C-Peptide Response Curve (GCRC) Phenotypes to Enhance Selection
Specificity for Type 1 Diabetes (T1D) Prevention Trials
David Baidal, MD
Chair – June 25, 2021
Theme Area: Clinical Diabetes/Therapeutics
Prevention of Diabetes and Diabetes Complications (With State-of-the-Art Lecture)
Chair- June 25, 2021
Theme Area: Clinical Diabetes/Therapeutics
Mental Health Disorders in Patients with Diabetes—A Most Challenging Mix
Chair – June 28, 2021
Theme Area: Clinical Diabetes/Therapeutics
Management of Atypical Diabetes
Allison Bayer, PhD
Co-chair – June 28, 2021
Professional Interest Group Discussion on Immunology, Immunogenetics, and Transplantation—Clinical Response Endotypes in Type 1 Diabetes
Jay Sosenko, MD
Senior Author – TrialNet
Poster Session Titles
11-OR Assessments of Pre-diagnostic Metabolic Measures as Surrogate Endpoints for Type 1 Diabetes (T1D) Prevention Trials
EMILY K. SIMS, DAVID D. CUTHBERTSON, LAURA M. JACOBSEN, KEVAN C. HEROLD, JAY SOSENKO, Indianapolis, IN, Tampa, FL, Gainesville, FL, New Haven, CT, Miami, FL
12-OR Metabolic Effects of Two Oral Insulin Dosing Regimens in Individuals at High Risk for Type 1 Diabetes (T1D)
MARIA J. REDONDO, JAY SOSENKO, EMILY K. SIMS, DAVID D. CUTHBERTSON, EDDIE A. JAMES, S. ALICE LONG, WILLIAM KWOK, LIPING YU, AARON W. MICHELS, ÅKE LERNMARK, PETER GOTTLIEB, Houston, TX, Miami, FL, Indianapolis, IN, Tampa, FL, Seattle, WA, Aurora, CO, Lund, Sweden
75-OR Marked Heterogeneity in Nondiabetic, Autoantibody-Positive (Ab+) Individuals with Dysglycemia: Implications for Type 1 Diabetes (T1D) Staging
MARIA J. REDONDO, DAVID D. CUTHBERTSON, BRANDON M. NATHAN, EMILY K. SIMS, MUSTAFA TOSUR, INGRID LIBMAN, JAY S. SKYLER, CARMELLA EVANS-MOLINA, MARK A. ATKINSON, JAY SOSENKO, Houston, TX, Tampa, FL, Minneapolis, MN, Indianapolis, IN, Pittsburgh, PA, Miami, FL, Gainesville, FL
589-P Effect of Oral Insulin (OI) on Combined Glucose and C-Peptide Endpoints in Individuals at High-Risk for Type 1 Diabetes (T1D)
LAURA M. JACOBSEN, DAVID D. CUTHBERTSON, EMILY K. SIMS, HEBA M. ISMAIL, LINDA DIMEGLIO, TAYLOR M. TRIOLO, MARIA J. REDONDO, MARKUS LUNDGREN, PETER GOTTLIEB, MARK A. ATKINSON, JEFFREY KRISCHER, DESMOND SCHATZ, JAY SOSENKO, Gainesville, FL, Indianapolis, IN, Aurora, CO, Houston, TX, Lund, Sweden, Tampa, FL, Miami, FL
1117-P Characterizing Glucose/C-Peptide Response Curve (GCRC) Phenotypes to Enhance Selection Specificity for Type 1 Diabetes (T1D) Prevention Trials